Mark Fishman | |
---|---|
Citizenship | United States |
Alma mater | Yale College, Harvard Medical School |
Known for | pioneering Zebrafish research in cardiology |
Awards | Institute of Medicine member, Fellow of the American Academy of Arts and Sciences |
Scientific career | |
Fields | Medicine, Cardiology |
Institutions | Novartis Institutes of BioMedical Research, Massachusetts General Hospital, Harvard Medical School |
Mark Fishman is an American cardiologist, a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the Massachusetts General Hospital for patients with complex medical disorders. [1] A researcher and clinician in cardiology, he is the previous president of the Novartis Institutes for BioMedical Research (NIBR), [2] the main research arm of Novartis Pharmaceuticals. [3]
Fishman was appointed president of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort. [4] He is the author of over 100 publications [5] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease. [6] [7] [8]
He was previously a professor of medicine at Harvard Medical School, chief of cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine. [9]
After being the head of Novartis for 13 years, he decided to retire in 2016 [10] and became professor at Harvard and Chief at MGH [1]
Mark Fishman | |
---|---|
Citizenship | United States |
Alma mater | Yale College, Harvard Medical School |
Known for | pioneering Zebrafish research in cardiology |
Awards | Institute of Medicine member, Fellow of the American Academy of Arts and Sciences |
Scientific career | |
Fields | Medicine, Cardiology |
Institutions | Novartis Institutes of BioMedical Research, Massachusetts General Hospital, Harvard Medical School |
Mark Fishman is an American cardiologist, a professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the Massachusetts General Hospital for patients with complex medical disorders. [1] A researcher and clinician in cardiology, he is the previous president of the Novartis Institutes for BioMedical Research (NIBR), [2] the main research arm of Novartis Pharmaceuticals. [3]
Fishman was appointed president of the newly founded Novartis Institutes for BioMedical Research in 2002 to implement a new strategy in Novartis' global drug discovery effort. [4] He is the author of over 100 publications [5] and known for pioneering research using the zebrafish as a means of visualizing the development of the circulatory system and as a model for human disease. [6] [7] [8]
He was previously a professor of medicine at Harvard Medical School, chief of cardiology at Massachusetts General Hospital, and director of the Cardiovascular Research Center at Massachusetts General Hospital. He is a fellow of the National Academy of Arts and Sciences and a member of the National Academy of Sciences, Institute of Medicine. [9]
After being the head of Novartis for 13 years, he decided to retire in 2016 [10] and became professor at Harvard and Chief at MGH [1]